Data Safety Monitoring Board Recommends Completion of Phase II Study to Evaluate the Efficacy and Safety of ARAKODA® (tafenoquine) for Treatment of Mild-Moderate Covid-19 Disease
Our team is committed to creating innovative, potentially lifesaving medicines to significantly impact the quality of life for those affected by tropical diseases worldwide.
Annual deaths from malaria globally
Travelers to endemic regions per annum
Dengue infections per year
1025 Connecticut Ave. NW, Suite 1000, Washington, DC 20036